These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 17971816)
41. Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma. Lal S; Raffel C Methods Mol Biol; 2022; 2423():165-177. PubMed ID: 34978698 [TBL] [Abstract][Full Text] [Related]
42. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor. Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845 [TBL] [Abstract][Full Text] [Related]
43. Monitoring the initial delivery of an oncolytic measles virus encoding the human sodium iodide symporter to solid tumors using contrast-enhanced computed tomography. Penheiter AR; Dingli D; Bender CE; Russell SJ; Carlson SK J Gene Med; 2012; 14(9-10):590-7. PubMed ID: 23015290 [TBL] [Abstract][Full Text] [Related]
44. Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Liu YP; Tong C; Dispenzieri A; Federspiel MJ; Russell SJ; Peng KW Cancer Gene Ther; 2012 Mar; 19(3):202-11. PubMed ID: 22116376 [TBL] [Abstract][Full Text] [Related]
45. Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs. LeBlanc AK; Naik S; Galyon GD; Jenks N; Steele M; Peng KW; Federspiel MJ; Donnell R; Russell SJ Hum Gene Ther Clin Dev; 2013 Dec; 24(4):174-81. PubMed ID: 24219832 [TBL] [Abstract][Full Text] [Related]
46. Oncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumors. Studebaker AW; Hutzen B; Pierson CR; Shaffer TA; Raffel C; Jackson EM Neuro Oncol; 2015 Dec; 17(12):1568-77. PubMed ID: 25838138 [TBL] [Abstract][Full Text] [Related]
47. Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy. Iankov ID; Blechacz B; Liu C; Schmeckpeper JD; Tarara JE; Federspiel MJ; Caplice N; Russell SJ Mol Ther; 2007 Jan; 15(1):114-22. PubMed ID: 17164782 [TBL] [Abstract][Full Text] [Related]
48. Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Qiao J; Wang H; Kottke T; White C; Twigger K; Diaz RM; Thompson J; Selby P; de Bono J; Melcher A; Pandha H; Coffey M; Vile R; Harrington K Clin Cancer Res; 2008 Jan; 14(1):259-69. PubMed ID: 18172278 [TBL] [Abstract][Full Text] [Related]
49. Modeling of cancer virotherapy with recombinant measles viruses. Bajzer Z; Carr T; Josić K; Russell SJ; Dingli D J Theor Biol; 2008 May; 252(1):109-22. PubMed ID: 18316099 [TBL] [Abstract][Full Text] [Related]
50. Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. Baldo A; Galanis E; Tangy F; Herman P Hum Vaccin Immunother; 2016 May; 12(5):1102-16. PubMed ID: 26631840 [TBL] [Abstract][Full Text] [Related]
51. Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Haralambieva I; Iankov I; Hasegawa K; Harvey M; Russell SJ; Peng KW Mol Ther; 2007 Mar; 15(3):588-97. PubMed ID: 17245355 [TBL] [Abstract][Full Text] [Related]
52. Enhanced antitumor effects of an engineered measles virus Edmonston strain expressing the wild-type N, P, L genes on human renal cell carcinoma. Meng X; Nakamura T; Okazaki T; Inoue H; Takahashi A; Miyamoto S; Sakaguchi G; Eto M; Naito S; Takeda M; Yanagi Y; Tani K Mol Ther; 2010 Mar; 18(3):544-51. PubMed ID: 20051938 [TBL] [Abstract][Full Text] [Related]
53. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. Myers R; Harvey M; Kaufmann TJ; Greiner SM; Krempski JW; Raffel C; Shelton SE; Soeffker D; Zollman P; Federspiel MJ; Blanco M; Galanis E Hum Gene Ther; 2008 Jul; 19(7):690-8. PubMed ID: 18576918 [TBL] [Abstract][Full Text] [Related]
54. Deficiency of caspase 3 in tumor xenograft impairs therapeutic effect of measles virus Edmoston strain. Wang B; Yan X; Guo Q; Li Y; Zhang H; Xie JS; Meng X Oncotarget; 2015 Jun; 6(18):16019-30. PubMed ID: 25909216 [TBL] [Abstract][Full Text] [Related]
55. Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Penheiter AR; Griesmann GE; Federspiel MJ; Dingli D; Russell SJ; Carlson SK Gene Ther; 2012 Mar; 19(3):279-87. PubMed ID: 21753796 [TBL] [Abstract][Full Text] [Related]
56. Therapeutic Applications for Oncolytic Self-Replicating RNA Viruses. Lundstrom K Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555262 [TBL] [Abstract][Full Text] [Related]